Share ownership Hangzhou Tigermed Consulting Co., Ltd

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-12			5-day change	1st Jan Change
55.81 ^CNY	-1.31%		-1.69%	-1.57%

Mar. 03	Frontage Laboratories, Inc. acquired Teddy Clinical Research Laboratory Co., Ltd from Hangzhou Tigermed Consulting Co., Ltd and Jiaxing Xinge Medical Consulting Co., Ltd.	CI
Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT

Share class: Hangzhou Tigermed Consulting Co., Ltd

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,124,800	123,124,800 ( 100 %)	0	72.37 %
Stock B	1	741,823,770	502,876,036 ( 67.79 %)	0

Major shareholders: Hangzhou Tigermed Consulting Co., Ltd

Name	Equities	%	Valuation
Xiao Ping Ye 31.1 %	177,239,541	31.1 %	1 542 M ¥
Xiao Chun Cao 9.004 %	51,314,174	9.004 %	446 M ¥
Zhong Ou Asset Management Co., Ltd 4.997 %	28,474,516	4.997 %	248 M ¥
Aegon-Industrial Fund Management Co., Ltd. 4.513 %	25,719,270	4.513 %	224 M ¥
Hwabao WP Fund Management Co., Ltd. 3.072 %	17,507,514	3.072 %	152 M ¥
China Merchants Fund Management Co., Ltd. 1.8 %	10,257,951	1.8 %	89 M ¥
Xiao Li Shi 1.759 %	10,023,021	1.759 %	87 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 1.73 %	9,858,516	1.73 %	86 M ¥
Tian Hong Asset Management Co., Ltd. 1.532 %	8,732,559	1.532 %	76 M ¥
China Asset Management Co., Ltd. 1.366 %	7,783,598	1.366 %	68 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Aegon-Industrial Fund Management Co., Ltd. 7.2 %	8,864,504	7.2 %	53 M ¥
JPMorgan Asset Management (Asia Pacific) Ltd. 6.791 %	8,361,600	6.791 %	50 M ¥
Industrial Securities Global Fund Management Co. Ltd. 6.735 %	8,292,315	6.735 %	50 M ¥
Ninety One UK Ltd. 6.141 %	7,560,500	6.141 %	45 M ¥
E Fund Management Co., Ltd. 4.929 %	6,068,900	4.929 %	37 M ¥
Sands Capital Management LLC 4.734 %	5,828,340	4.734 %	35 M ¥
Canada Pension Plan Investment Board 4.71 %	5,798,893	4.71 %	35 M ¥
OrbiMed Advisors LLC 2.622 %	3,228,767	2.622 %	19 M ¥
China Southern Asset Management Co., Ltd. 1.721 %	2,118,600	1.721 %	13 M ¥
HuaAn Fund Management Co., Ltd. 1.449 %	1,783,600	1.449 %	11 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Asia Growth Capital Management AB 0.0162 %	20,000	0.0162 %	120 320 ¥

Name	Equities	%	Valuation
Xiao Ping Ye 74.09 %	132,929,656	74.09 %	1 156 M ¥
Xiao Chun Cao 21.6 %	38,746,330	21.6 %	337 M ¥

Breakdown by shareholder type

Individuals	333.2%
Institutional	171.52%
Other	6.73%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	333.13%
China	143.05%
Hong Kong	15.36%
United States	7.36%
United Kingdom	7.14%
Canada	4.71%
Taiwan	0.25%
Singapore	0.17%
Ireland	0.06%
New Zealand	0.06%
Sweden	0.02%
Austria	0.02%
United Arab Emirates	0.01%
Japan	0.01%
Malaysia	0.01%
Denmark	0.01%

Based on 1000 largest holdings

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Employees

10,185

Sector

Biotechnology & Medical Research

Calendar

Mar. 31 - Earnings release - Annual 2025

More about the company